Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
- PMID: 32533071
- PMCID: PMC7290143
- DOI: 10.1038/s41429-020-0336-z
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Abstract
Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years. Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2. Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?Cells. 2020 Sep 15;9(9):2100. doi: 10.3390/cells9092100. Cells. 2020. PMID: 32942671 Free PMC article. Review.
-
The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?Biochem Biophys Res Commun. 2021 Jan 29;538:163-172. doi: 10.1016/j.bbrc.2020.10.042. Epub 2020 Oct 21. Biochem Biophys Res Commun. 2021. PMID: 33341233 Free PMC article. Review.
-
The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.Drug Res (Stuttg). 2020 Aug;70(8):337-340. doi: 10.1055/a-1185-8913. Epub 2020 Jun 19. Drug Res (Stuttg). 2020. PMID: 32559771 Free PMC article.
-
A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.Fundam Clin Pharmacol. 2021 Apr;35(2):260-276. doi: 10.1111/fcp.12644. Epub 2021 Jan 28. Fundam Clin Pharmacol. 2021. PMID: 33427370 Free PMC article. Review.
-
Antivirals that _target the host IMPα/β1-virus interface.Biochem Soc Trans. 2021 Feb 26;49(1):281-295. doi: 10.1042/BST20200568. Biochem Soc Trans. 2021. PMID: 33439253 Free PMC article. Review.
Cited by
-
Computational Drug Design Strategies for Fighting the COVID-19 Pandemic.Adv Exp Med Biol. 2024;1457:199-214. doi: 10.1007/978-3-031-61939-7_11. Adv Exp Med Biol. 2024. PMID: 39283428
-
Antiviral Potential of Nanoparticles-Can Nanoparticles Fight Against Coronaviruses?Nanomaterials (Basel). 2020 Aug 21;10(9):1645. doi: 10.3390/nano10091645. Nanomaterials (Basel). 2020. PMID: 32825737 Free PMC article. Review.
-
White paper on Ivermectin as a potential therapy for COVID-19.Indian J Tuberc. 2020 Jul;67(3):448-451. doi: 10.1016/j.ijtb.2020.07.031. Indian J Tuberc. 2020. PMID: 32825892 Free PMC article.
-
Effectiveness and safety of ivermectin in the treatment of COVID-19: protocol for a systematic review and meta-analysis.BMJ Open. 2021 Sep 17;11(9):e050532. doi: 10.1136/bmjopen-2021-050532. BMJ Open. 2021. PMID: 34535482 Free PMC article.
-
Comparative study of the interaction of ivermectin with proteins of interest associated with SARS-CoV-2: A computational and biophysical approach.Biophys Chem. 2021 Nov;278:106677. doi: 10.1016/j.bpc.2021.106677. Epub 2021 Aug 19. Biophys Chem. 2021. PMID: 34428682 Free PMC article.
References
-
- Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15:325–32. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous